To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Farber disease
Farber disease (also known as Farber's lipogranulomatosis or ceramidase deficiency) describes a group of rare autosomal recessive disorders that cause an accumulation of lipids in the joints, tissues and central nervous system. Additional recommended knowledge
Diagnosis and symptomsDisease onset is typically in early infancy but may occur later in life. Children who have the classic form of Farber disease develop neurological shnapps within the first few weeks of life. These symptoms may include moderately impaired mental ability and problems with swallowing. The liver, heart and kidneys may also be affected. Other symptoms may include vomiting, arthritis, swollen lymph nodes, swollen joints, joint contractures (chronic shortening of muscles or tendons around joints), hoarseness and xanthemas which thicken around joints as the disease progresses. Patients with breathing difficulty may require a breathing tube. PrognosisMost children with the disease die by age 2, usually from lung disease. In one of the most severe forms of the disease, an enlarged liver and spleen (hepatosplenomegaly) can be diagnosed soon after birth. Children born with this form of the disease usually die within 6 months. TreatmentThere is no specific treatment for Farber disease. Corticosteroids may be prescribed to relieve pain. Bone marrow transplants may improve granulomas (small masses of inflamed tissue) on patients with little or no lung or nervous system complications. Older patients may have granulomas surgically reduced or removed. EponymIt is named for Sidney Farber.[1][2] References
|
|||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Farber_disease". A list of authors is available in Wikipedia. |
- MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
- Devgen and Dogal receive regulatory approval in Turkey for the use of Devgen's nematicide product Devguard
- Gen-Schere soll SARS-CoV2 und andere RNA-Viren zerstören - Quantensprung im Kampf gegen Viren: Wissenschaftler aus Göttingen und Hannover überzeugen im ersten bundesweiten Innovationswettbewerb SprinD-Challenge
- Covid-19 risk increases with airborne pollen - Increased pollen concentrations correlate with higher SARS-CoV-2 infection rates
- Lonza Announces New Addition to Executive Committee - Sven Abend will join Lonza and serve on the Executive Committee with primary responsibility for Corporate Strategy and Business Development